The anticoagulants market is set to witness exponential growth over the forecast time period due to increased acceptability of newer class of non-vitamin K oral anticoagulants and increasing product usage in coronary artery disease, atrial fibrillation/flutter, and venous thromboembolism among others. Anticoagulants are basically medicines that help in preventing blood from clotting.

These medicines are given to patients who are at a higher risk of getting blood clots, as well as to decrease their chances of developing any serious conditions like heart attacks and strokes. Anticoagulants generally work by interposing the process that is involved in the blood clots formation. These are also known as blood thinning medicines and are known to be very different from antiplatelet medicines like clopidogrel and low-dose aspirin.

The anticoagulants market is segmented in terms of drug class, route of administration, application, distribution channel, and regional landscape.

With respect to drug class the market for anticoagulants is classified into direct thrombin inhibitor, warfarin (Vitamin K antagonist), factor Xa inhibitor, heparins, and others. In 2020, the warfarin segment accounted for a market share of 1.8% and is estimated to follow a strong growth trend over the coming years. Vitamin K antagonists help to stop the liver from processing vitamin K into essential factors that usually help in clotting the blood. This further controls blood clotting.

One of the main advantages of this type of anticoagulant drug class is that it is far easier than other types to reverse in case of sudden bleeding from emergency or trauma surgery.

Based on route of administration the anticoagulants market is divided into injectables and oral. Among these, the oral anticoagulants segment accounted for a valuation of more than $14.2 billion in 2020 and is estimated to foresee lucrative growth over the upcoming years.

In terms of application the overall anticoagulants market is categorized into coronary artery disease, AF/flutter, venous thromboembolism, and others. Here, the AF (atrial fibrillation)/flutter segment is expected to reach approximately $14.1 billion valuation by the end of 2027. Anticoagulants or blood thinning medicines have been highly recommended to decrease the risk of stroke in patients diagnosed with atrial fibrillation who have higher risk of thromboembolism or/and stroke caused by blocked arteries.

With respect to distribution channel, the market is bifurcated into online pharmacy, retail pharmacy, and hospital pharmacy. Hospital pharmacy is projected to exhibit a steady growth rate of 6.0% during the analysis period.

From a regional frame of reference, in 2020, Latin America anticoagulants market accounted for a market share of 1.3% and is estimated to follow a strong growth trend over the coming years.

Meanwhile the anticoagulants market in Middle East & Africa generated revenue of $372.6 million in 2020 and will continue to follow appreciative growth over the coming years.